Combined cytotoxic chemotherapy and immunotherapy of cancer: modern times

Bailly, Christian; Thuru, Xavier; Quesnel, Bruno

Document type :

Compte-rendu et recension critique d'ouvrage

DOI :

10.1093/narcan/zcaa002

Permalink :

http://hdl.handle.net/20.500.12210/108109

Title :

Combined cytotoxic chemotherapy and immunotherapy of cancer: modern times

Author(s) :

Bailly, Christian [Auteur]
Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U837 [JPArc]
Thuru, Xavier [Auteur]

Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U837 [JPArc]
Quesnel, Bruno [Auteur]

Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U837 [JPArc]

Journal title :

NAR Cancer

Pages :

zcaa002

Publisher :

Oxford University Press

Publication date :

2020-03-01

HAL domain(s) :

Sciences du Vivant [q-bio]/Immunologie

English abstract : [en]

Monoclonal antibodies targeting programmed cell death 1/programmed cell death ligand 1 (PD-1/PD-L1) immune checkpoints have improved the treatments of cancers. However, not all patients equally benefit from immunotherapy. ...
Show more >Monoclonal antibodies targeting programmed cell death 1/programmed cell death ligand 1 (PD-1/PD-L1) immune checkpoints have improved the treatments of cancers. However, not all patients equally benefit from immunotherapy. The use of cytotoxic drugs is practically inevitable to treat advanced cancers and metastases. The repertoire of cytotoxics includes 80 products that principally target nucleic acids or the microtubule network in rapidly proliferating tumor cells. Paradoxically, many of these compounds tend to become essential to promote the activity of immunotherapy and to offer a sustained therapeutic effect. We have analyzed each cytotoxic drug with respect to effect on expression and function of PD-(L)1. The major cytotoxic drugs—carboplatin, cisplatin, cytarabine, dacarbazine, docetaxel, doxorubicin, ecteinascidin, etoposide, fluorouracil, gemcitabine, irinotecan, oxaliplatin, paclitaxel and pemetrexed—all have the capacity to upregulate PD-L1 expression on cancer cells (via the generation of danger signals) and to promote antitumor immunogenicity, via activation of cytotoxic T lymphocytes, maturation of antigen-presenting cells, depletion of immunosuppressive regulatory T cells and/or expansion of myeloid-derived suppressor cells. The use of ‘immunocompatible’ cytotoxic drugs combined with anti-PD-(L)1 antibodies is a modern approach, not only for increasing the direct killing of cancer cells, but also as a strategy to minimize the activation of immunosuppressive and cancer cell prosurvival program responses.Show less >

Language :

Anglais

Popular science :

Non

Collections :

Submission date :

2024-02-17T04:30:49Z

Files

pdf
Open access
Access the document

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8209987/pdf
Open access
Access the document

zcaa002.pdf
Open access
Access the document

document
Open access
Access the document

Combined cytotoxic chemotherapy and ... BibTeX CSV Excel RIS

Files

Combined cytotoxic chemotherapy and ...

BibTeX

CSV

Excel

RIS